ArticlePharmaceuticals (Basel, Switzerland)2020
Epigallocatechin-3-Gallate-Loaded Gold Nanoparticles: Preparation and Evaluation of Anticancer Efficacy in Ehrlich Tumor-Bearing Mice.
Article in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- EGCG as a therapeutic agent: a systematic review of recent advances and challenges in nanocarrier strategies.Journal of Zhejiang University. Science. B · 2025Pooled it
- A Systematic Review and Meta-Analysis of the Metal Nano-Particles Loaded with Herbal Drugs Moieties Against Breast Cancer.Recent patents on nanotechnology · 2025Pooled it
- Sustainable gold nanoparticles using Jania rubens, targeted therapeutic potential in prostate cancer and mechanistic insights via GO/KEGG pathway analysis.Scientific reports · 2026Article
- Physicochemical and Antioxidant Alterations of Modified and Free Epigallocatechin Gallate Under Thermal Treatment in Air and Vacuum.Journal of functional biomaterials · 2025Article
- Epigallocatechin-3-gallate ameliorates lipopolysaccharide-induced inflammation via the 67LR/JAK2/STAT3 signaling pathway.Scientific reports · 2025Article
- Emerging phytochemical-based nanocarriers: redefining the perspectives of breast cancer therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Advanced Targeted Drug Delivery of Bioactive Agents Fortified with Graft Chitosan in Management of Cancer: A Review.Current medicinal chemistry · 2025Review
- In vitro results with minimal blood toxicity of a combretastatin A4 analogue.Investigational new drugs · 2024Article
- Unveiling of the Anti-Tumor Activity of Green Synthesized Zinc Nanoparticles against Ehrlich Solid Tumors in Mice.Archives of Razi Institute · 2024Article
- Review
- Special Issue "Nanoparticle-Mediated Drug Delivery, Imaging, and Control of Cellular Functions".Pharmaceuticals (Basel, Switzerland) · 2023Article
- Pharmacological Role of Functionalized Gold Nanoparticles in Disease Applications.Molecules (Basel, Switzerland) · 2022Review
- Nanocarriers Based on Gold Nanoparticles for Epigallocatechin Gallate Delivery in Cancer Cells.Pharmaceutics · 2022Article
- Effective Cancer Management: Inimitable Role of Phytochemical Based Nano- Formulations.Current drug metabolism · 2022Review
- Evaluation of the synergistic effects of epigallocatechin-3-gallate-loaded PEGylated-PLGA nanoparticles with nimodipine against neuronal injury after subarachnoid hemorrhage.Frontiers in nutrition · 2022Article
- Hyaluronic Acid-Modified and Doxorubicin-Loaded Gold Nanoparticles and Evaluation of Their Bioactivity.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Formulation and Optimization of Nanospanlastics for Improving the Bioavailability of Green Tea Epigallocatechin Gallate.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Development and Optimization of Epigallocatechin-3-Gallate (EGCG) Nano Phytosome Using Design of Experiment (DoE) and Their In Vivo Anti-Inflammatory Studies.Molecules (Basel, Switzerland) · 2020Article
- Plant-Derived Natural Products in Cancer Research: Extraction, Mechanism of Action, and Drug Formulation.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epigallocatechin-3-gallate (EGCG) is a pleiotropic compound with anticancer, anti-inflammatory, and antioxidant properties. To enhance EGCG anticancer efficacy, it was loaded onto gold nanoparticles (GNPs). EGCG-GNPs were prepared by a simple green synthesis method and were evaluated using different techniques. Hemocompatibility with human blood and in vivo anticancer efficacy in Ehrlich ascites carcinoma-bearing mice were evaluated. EGCG/gold chloride molar ratio had a marked effect on the formation and properties of EGCG-GNPs where well-dispersed spherical nanoparticles were obtained at a molar ratio not more than 0.8:1. The particle size ranged from ~26 to 610 nm. High drug encapsulation efficiency and loading capacity of ~93 and 32%, respectively were obtained. When stored at 4 °C for three months, EGCG-GNPs maintained over 90% of their drug payload and had small changes in their size and zeta potential. They were non-hemolytic and had no deleterious effects on partial thromboplastin time, prothrombin time, and complement protein C3 concentration. EGCG-GNPs had significantly better in vivo anticancer efficacy compared with pristine EGCG as evidenced by smaller tumor volume and weight and higher mice body weight. These results confirm that EGCG-GNPs could serve as an efficient delivery system for EGCG with a good potential to enhance its anticancer efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.